Celgene's (CELG +1.6%) Abraxane breast cancer treatment for patients with metastatic melanoma...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene's (CELG +1.6%) Abraxane breast cancer treatment for patients with metastatic melanoma met its primary endpoint of "progression-free survival" in a Phase III trial that compared the medicine with acarbazine chemotherapy. (PR)